Alithea Biotechnology GmbH is a pioneer in the characterization of HLA-presented peptides and AI solutions for their discovery, for target validation and off-target toxicity. With Alithea's AI-guided technology, we aim to provide best drugs to each patient. 

Alithea is supporting biotech and pharma companies in their quest for more effective and save TCR and TCRm immunotherapy.
We are experts in the absolute quantification of HLA peptides, and have the world's largets HLA peptide database for off-target toxicity prediction, target discovery and target validation.

Similarly, Alithea has highly sensitive neoantigen detection pipeline, NeoZoom, that can be used to optimize cancer vaccine development. 

HLA-Compass, Alithea's SaaS platform is the largest quantitative database of HLA peptide presentation in healthy and tumor tissues. Besides target discovery and validation, it offers a suite of tools for off-target/safety evaluations. 

HLA peptides are finally also important to understand potential immunogenicity risk of biotherapeutics. Profiling HLA class II presented peptides from therapeutic proteins allows to determine sequences that feature a risk to lead to immunogenicity in patients and thereby lower efficacy.

Alithea Bio

Org chart

Teams

Offices